Business Context and Reporting Period
Company: Intellia Therapeutics, Inc. (NTLA)
Filing Type: Form 8-K (Current Report)
Date of Report: September 4, 2026
Event: Entry into a Material Definitive Agreement (Credit Agreement) with OrbiMed Royalty & Credit Opportunities V, LP as administrative agent.
Key Financial Metrics and Facility Details
This filing details a new debt facility rather than reporting period-end financial results (revenue, profit, or cash flow). Key terms of the Credit Facility include:
- Total Facility Size: Up to $400 million senior secured credit facility.
- Initial Draw: $75 million drawn on the Closing Date (September 4, 2026).
- Interest Rate: Greater of 3.00% or one-month SOFR plus an applicable margin of 6.15%.
- Maturity Date: September 4, 2031.
- Collateral: First-priority security interest in substantially all assets, including intellectual property.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Facility Structure
The Company has secured a non-dilutive debt instrument structured with milestone-based tranches:
- Tranche 2: Potential $75 million upon FDA approval of the BLA for lonvoguran ziclumeran ("lonvo-z").
- Tranche 3: Three potential $40 million draws ($120 million total) upon achieving specific revenue targets for lonvo-z.
- Tranche 4: Potential $30 million upon achieving an equity fundraising target.
- Tranche 5: Uncommitted incremental facility up to $100 million subject to mutual agreement.
Liquidity Covenant: The Company must maintain liquidity of at least $50 million in controlled accounts until FDA approval of the lonvo-z BLA.
Guidance, Risks, and Covenants
Covenants: The agreement includes negative covenants restricting additional indebtedness, liens, investments, mergers, asset sales, and dividends. Exceptions exist for synthetic royalty transactions.
Events of Default: Include payment defaults, material inaccuracy of representations, covenant defaults, bankruptcy, cross-defaults, and change of control.
Forward-Looking Risks: The ability to access additional funding tranches is contingent on regulatory approvals (FDA), revenue targets, and equity fundraising. Actual results may differ due to market conditions and uncertainties regarding the approval of lonvo-z for hereditary angioedema.
Investor Verification Checklist
- Verify the exact interest rate calculation (SOFR + 6.15% vs. 3.00% floor) for the initial draw period.
- Confirm the specific revenue targets and dates required to unlock the three $40 million tranches.
- Review the definition of "controlled accounts" to understand the $50 million liquidity maintenance requirement.
- Assess the impact of the first-priority lien on intellectual property on future financing or partnership opportunities.
- Monitor the status of the FDA BLA for lonvo-z as the trigger for the $75 million milestone draw.